Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

(2021) Raches Ella et al.   LANCET INFECTIOUS DISEASES

SARS-CoV-2 Vaccines

(2021) C. Buddy Creech et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

(2021) Zhiwei Wu et al.   LANCET INFECTIOUS DISEASES

Association of Age With SARS-CoV-2 Antibody Response

(2021) He S. Yang et al.   JAMA Network Open

Coronavirus Infections in Children Including COVID-19

(2020) Petra Zimmermann et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Development of an inactivated vaccine candidate for SARS-CoV-2

(2020) Qiang Gao et al.   SCIENCE

Multisystem Inflammatory Syndrome in Children (MIS-C) with COVID-19: Insights from simultaneous familial Kawasaki Disease cases

(2020) R. Ebina-Shibuya et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes

(2020) Shengli Xia et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

(2020) Shengli Xia et al.   LANCET INFECTIOUS DISEASES

Children and Adolescents With SARS-CoV-2 Infection

(2020) Helena C. Maltezou et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

COVID-19 in children and young people

(2020) Matthew D. Snape et al.   SCIENCE

An Effective COVID-19 Vaccine Needs to Engage T Cells

(2020) Karsten Sauer et al.   Frontiers in Immunology

COVID-19 vaccine development

(2020) Satoshi Kamidani et al.   CURRENT OPINION IN PEDIATRICS

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

(2020) Yanjun Zhang et al.   LANCET INFECTIOUS DISEASES

Comparison of the effect of increased hepatitis B vaccine dosage on immunogenicity in healthy children and adults

(2016) Guodong Kang et al.   Human Vaccines & Immunotherapeutics

Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis

(2015) Olivier Van Der Meeren et al.   Human Vaccines & Immunotherapeutics

Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: A randomized, placebo-controlled, double-blind, Phase I clinical trial

(2012) Yan-Ping Li et al.   VACCINE